PANACEA LIFE SCIENCES HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $1.15M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2019 Ended Sep 30, 2019 | Nov 14, 2019 | During market hours | – | – | – |
Press releases
Announcements Panacea Life Sciences filed with the SEC
Life Sciences and Sky Wellness Enter Agreement for Licensing, Marketing, Supply and Development of Sky Wellness CBD Products
Material agreement · Other events · EX-99.1 to Form 8-K
Life Sciences Holdings, Inc. Completes Acquisition of N7 Enterprises With Eight Natural Health and Wellness Retail and One Distribution
Material agreement · Acquisition or disposition completed · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Life Sciences Holdings, Inc. Continues Growth Trajectory with Acquisition of the PÜR LIFE Medical Franchise
Material agreement · Other events · EX-99.1 to Form 8-K
Life Sciences Holdings, Inc. Adopts Diversification Plan: Vegan, Organic, Nutraceuticals, Alternative Health and Wellness Products and
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Life Sciences Holdings, Inc. Enters Into Agreement to Natural Health and Wellness Chain of Retail Locations in Tampa, Florida
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Material agreement · Regulation FD disclosure · EX-99.3 to Form 8-K
Announces Letter of Intent to Acquire N7 Enterprises, Inc.
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
financial statements of Panacea Life Sciences, Inc. for the years ended December 31, 2020 and 2019
Other events · EX-99.2 to Form 8-K/A
pro forma condensed combined financial information
Other events · EX-99.4 to Form 8-K/A